Metabolic complications of antiretroviral therapy

Thesis

Cover

Titlepage

Contents

1 General Introduction

2 Increased risk of lipodystrophy when including nucleoside analogue reverse transcriptase inhibitors in the treatment of HIV-1 infection with protease inhibitors

3 Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

4 Lipid profiles associated with antiretroviral drug choices

5 Lipodystrophy in HIV-1 positive subjects is associated with insulin resistance in multiple metabolic pathways

6 Highly active antiretroviral therapy-induced lipodystrophy has minor effects on HIV induced changes in lipolysis but normalises resting energy expenditure

7 Mitochondrial DNA content in blood and subcutaneous fat of HIV-1 infected patients randomly allocated to zidovudine-or stavudine-based therapy: possible implications for lipodystrophy pathogenesis

8 Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution following extended discontinuation of protease inhibitors in severe lipodystrophic HIV-1 infected patients

9 General Discussion

10 Summary

11 Nederlandse samenvatting Dankwoord Publicatie lijst Curriculum Vitae

Cover